Replies to post #46647 on Biotech Values

[DewDiligence]

Quiz answer:

>>
1. Generic polysaccharide drugs
2. Generic polypeptide drugs
3. Generic glycoprotein drugs
What is all this in reference to?
<<

This is the progression in MNTA’s business model from easiest to hardest.

Step #1 has already reached the ANDA submission stage for generic Lovenox.

Step #2 is under development with partner NVS to create a generic version of Copaxone. An ANDA will follow.

Step #3 is in early development using two undisclosed glycoproteins designated by NVS. The regulatory path is not yet established.